Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 3
2018 4
2019 8
2020 13
2021 5
2022 13
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
CIC-DUX4 sarcomas.
Brahmi M, Vanacker H, Macagno N, Tirode F, Dufresne A. Brahmi M, et al. Curr Opin Oncol. 2022 Jul 1;34(4):342-347. doi: 10.1097/CCO.0000000000000855. Epub 2022 Jun 22. Curr Opin Oncol. 2022. PMID: 35730520 Review.
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Kang YK, et al. Among authors: brahmi m. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343033 Free PMC article. Clinical Trial.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: brahmi m. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
Fazel M, Dufresne A, Vanacker H, Waissi W, Blay JY, Brahmi M. Fazel M, et al. Among authors: brahmi m. Cancers (Basel). 2023 Mar 7;15(6):1643. doi: 10.3390/cancers15061643. Cancers (Basel). 2023. PMID: 36980528 Free PMC article. Review.
[Therapeutic targeting of Notch signaling in cancer].
Brahmi M, Bally O, Eberst L, Cassier P. Brahmi M, et al. Bull Cancer. 2017 Oct;104(10):883-891. doi: 10.1016/j.bulcan.2017.07.007. Epub 2017 Oct 12. Bull Cancer. 2017. PMID: 29031504 Review. French.
Prognostic Factors for Local Recurrence after Cryoablation of Desmoid Tumors.
Bouhamama A, Wdowik Q, Grillet F, Brahmi M, Sunyach MP, Vaz G, Meeus P, Gouin F, Corradini N, Dufresne A, Chabaud S, Blay JY, Pilleul F. Bouhamama A, et al. Among authors: brahmi m. J Vasc Interv Radiol. 2023 Sep;34(9):1538-1546. doi: 10.1016/j.jvir.2023.05.012. Epub 2023 May 12. J Vasc Interv Radiol. 2023. PMID: 37182669
New Drug Approvals for Sarcoma in the Last 5 Years.
Thirasastr P, Brahmi M, Dufresne A, Somaiah N, Blay JY. Thirasastr P, et al. Among authors: brahmi m. Surg Oncol Clin N Am. 2022 Jul;31(3):361-380. doi: 10.1016/j.soc.2022.03.003. Surg Oncol Clin N Am. 2022. PMID: 35715139 Review.
[Bispecific antibodies targeting CD3 in oncology and hematology].
Vanacker H, Vinceneux A, Nicolas-Virelizier E, Brahmi M, Cassier PA. Vanacker H, et al. Among authors: brahmi m. Bull Cancer. 2021 Oct;108(10S):S181-S194. doi: 10.1016/j.bulcan.2021.06.003. Bull Cancer. 2021. PMID: 34920802 Review. French.
57 results